{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-211860","form_type":"8-K","ticker":"AMGN","cik":"0000318154","company_name":"AMGEN INC","filed_at":"2022-08-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:57.764921+00:00","generated_at":"2026-06-24T04:33:35.115398+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Amgen to acquire ChemoCentryx for $52/share (~$3.7B) including TAVNEOS","bullets":["Amgen will pay $52 per share in cash, enterprise value ~$3.7B; deal unanimously approved by both boards.","TAVNEOS (avacopan) is a first-in-class oral C5aR inhibitor approved Oct 2021 for ANCA-associated vasculitis; Q1 2022 US sales $5.4M.","Transaction expected to close Q4 2022, subject to ChemoCentryx stockholder approval, HSR clearance, and other conditions.","ChemoCentryx must pay Amgen a termination fee of ~$119M if it terminates for a superior proposal or under certain circumstances.","Acquisition includes early-stage pipeline: three inflammatory disease candidates and an oral checkpoint inhibitor for cancer."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-211860","json":"https://secwatch.observer/filing/0001193125-22-211860.json","markdown":"https://secwatch.observer/filing/0001193125-22-211860.md","text":"https://secwatch.observer/filing/0001193125-22-211860.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/318154/000119312522211860/0001193125-22-211860-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/318154/000119312522211860/d346334d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T04:33:35.115398+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}